Hypothesis\n\nPersistent heterochromatin marks at the X chromosome and imprinted loci resist OSKM‑driven demethylation during reprogramming. We propose that the histone methyltransferases SETDB1 (H3K9me3) and EZH2 (H3K27me3) maintain repressive chromatin that limits OSKM access, causing the observed epigenetic gaps. Inhibiting these enzymes during the early phase of reprogramming should enhance erasure of allele‑specific methylation, improve X‑chromosome reactivation, and reduce tumorigenic potential.\n\n## Mechanistic rationale\n\n- OSKM factors pioneer open chromatin but are hindered by dense H3K9me3/H3K27me3 domains.\n- SETDB1 deposits H3K9me3 at repetitive X‑chromosome regions (e.g., q28) and at imprinting control regions.\n- EZH2 catalyzes H3K27me3, reinforcing a polycomb‑repressed state that blocks DNA demethylation.\n- Transient inhibition (e.g., using the SETDB1 inhibitor chalcone‑derived compound or EZH2 inhibitor GSK126) during days 3‑7 of OSKM expression—when age‑related epigenetic resetting begins—should allow OSKM to bind these loci, leading to passive demethylation during DNA replication.\n\n## Experimental design\n\n1. Cell system – Mouse neural progenitor iPSCs (low passage) and human fibroblasts.\n2. Reprogramming protocol – Doxycycline‑inducible OSKM; add inhibitor or DMSO control from day 3 to day 7.\n3. Readouts\n - Whole‑genome bisulfite sequencing (WGBS) focusing on X‑chr regions p11.23, q13.1, q22.3, q25/q26.1, q28 and known imprinting control regions (ICRs).\n - RNA‑seq to assess X‑linked gene expression and imprinting allele‑specific expression.\n - Telomere length and mitochondrial membrane potential as controls for general rejuvenation.\n - Differentiation assays toward hematopoietic lineages to test memory bias.\n - Teratoma formation in immunodeficient mice to quantify tumorigenicity.\n\n## Expected outcomes\n\n- If hypothesis is correct: inhibitor‑treated iPSCs show ≥30 % reduction in methylation at the specified X‑chr loci and ICRs compared with controls, accompanied by biallelic expression of previously silenced X‑linked genes and loss of parent‑of‑origin bias at imprinted loci.\n- Corresponding functional gains: increased hematopoietic differentiation efficiency and decreased teratoma incidence.\n- Falsification: No significant change in methylation or expression patterns despite inhibitor treatment, or worsened reprogramming efficiency, would refute the model.\n\n## Broader implications\n\nTargeting heterochromatin writers could narrow the rejuvenation gap, making iPSC‑based therapies safer by erasing residual somatic memory and reducing tumorigenic risk. This approach directly tests whether the epigenetic barriers are enzymatically maintained rather than passive remnants of the donor epigenome.\n\n## References\n\n- Transient OSKM rejuvenation 1\n- X‑chromosome methylation resistance 2\n- Residual methylation biases differentiation 3\n- Epigenetic memory passage dependence 4\n- Stochastic methylation variation 5